Palvella Therapeutics, Inc. (PVLA): EPS (Diluted)
-$3.71
Year ended 2025-12-31
| Period ended | EPS (Diluted) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$3.71 | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$7.83 | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $2.17 | n/c | 2025-03-31, From 2023-01-01 |
| No annual figure between 2021-12-31 and 2023-12-31. | |||
| 2021-12-31 | -$0.71 | n/m | 2022-03-02, From 2021-01-01 |
| 2020-12-31 | -$0.68 | n/a | 2022-03-02, From 2020-01-01 |
EPS (Diluted) at similar companies
| Company | Year ended | EPS (Diluted) | Change YoY |
|---|---|---|---|
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | -$3.71 | n/m |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | -$1.74 | n/m |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | -$1.90 | n/m |
| Scynexis Inc (SCYX) | 2025-12-31 | -$0.17 | n/m |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | -$2.91 | n/m |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | -$0.45 | n/m |
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | -$1.18 | n/m |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $2.42 | n/m |
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | -$1.16 | n/m |
Compare PVLA, PRPH, ALXO, SCYX side by side · Screen every company in Pharmaceutical Preparations ↗